



Advancing Research. Improving Lives.™

TO: ALL PRINCIPAL INVESTIGATORS, NURSES AND DATA MANAGERS

FROM: Protocol Development and Regulatory Compliance

DATE: July 25, 2024

RE: PROTOCOL NRG-GI007 – CLOSURE

Effective immediately, NRG-GI007, “Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery,” is closed to accrual, because it has reached its accrual target.

Reminders:

- Data collection and site IRB renewal for closed studies must continue until the study is terminated.
- Sites that do not have active patients on treatment must obtain written authorization from Oncolys before destruction of unused clinical material supplies. See protocol Appendix I/Pharmacy Manual, and Appendix IV/ Guidelines for Use and Completion of Clinical Trial Material (Drug) Destruction Certificate for further details. The Clinical Trial Material Destruction Certificate is located on the NRG Oncology website study-specific webpage.

Please distribute this information to the appropriate personnel at participating affiliate institutions.